HC Wainwright Reiterates Buy Rating for MediWound (NASDAQ:MDWD)

MediWound (NASDAQ:MDWD)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 151.22% from the stock’s previous close.

Several other research firms have also weighed in on MDWD. Wall Street Zen lowered shares of MediWound from a “hold” rating to a “strong sell” rating in a report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Tuesday, April 21st. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $32.00 target price on shares of MediWound in a report on Wednesday. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, MediWound presently has an average rating of “Hold” and a consensus target price of $34.00.

MediWound Trading Down 14.1%

MDWD opened at $14.33 on Thursday. MediWound has a 12-month low of $14.14 and a 12-month high of $22.50. The firm has a market capitalization of $184.17 million, a PE ratio of -6.82 and a beta of 0.21. The firm has a 50 day moving average of $16.73 and a two-hundred day moving average of $17.48.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.42. The company had revenue of $1.48 million during the quarter, compared to analyst estimates of $3.37 million. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. During the same period last year, the firm posted ($0.07) EPS. As a group, analysts predict that MediWound will post -2.75 EPS for the current fiscal year.

Institutional Investors Weigh In On MediWound

Institutional investors have recently added to or reduced their stakes in the stock. Quarry LP acquired a new stake in MediWound in the 4th quarter valued at $26,000. BNP Paribas Financial Markets boosted its stake in MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in MediWound during the 4th quarter worth $109,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.